CONTINUOUS AND FIXED-CYCLE DOSING OF INTRAVENOUS EFGARTIGIMOD FOR GENERALIZED MYASTHENIA GRAVIS: STUDY DESIGN OF ADAPT NXT

被引：0
|
作者：
Sahagian, Gregory [1 ]
Hussain, Yessar [2 ]
Feinberg, Marc H. [3 ]
Habib, Ali A. [4 ]
Skripuletz, Thomas [5 ]
Ruck, Tobias [6 ]
Brauer, Edward [7 ]
Gelinas, Deborah [7 ]
Liu, Li [7 ]
Podhorna, Jana [7 ]
Mantegazza, Renato [8 ]
机构：
[1] Neurol Ctr Southern Calif, Carlsbad, CA USA
[2] Austin Neuromuscular Ctr, Austin, TX USA
[3] South Florida Neurol Associates, Boca Raton, FL USA
[4] Univ Calif Irvine, Dept Neurol, Irvine, CA USA
[5] Hannover Med Sch, Hannover, Germany
[6] Heinrich Heine Univ, Dept Neurol, Fac Med, Dusseldorf, Germany
[7] argenx, Ghent, Belgium
[8] Fdn IRCCS Ist Neurol Carlo Besta, Dept Neuroimmunol & Neuromuscular Dis, Milan, Italy
来源：
MUSCLE & NERVE | 2022年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S14 / S14
页数：1
相关论文
共 50 条
  • [41] Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT)
    Francesco Saccà
    Carolina Barnett
    Tuan Vu
    Stojan Peric
    Glenn A. Phillips
    Sihui Zhao
    Cynthia Z. Qi
    Deborah Gelinas
    Silvia Chiroli
    Jan J. G. M. Verschuuren
    Journal of Neurology, 2023, 270 : 2096 - 2105
  • [42] Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT plus ): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
    Howard Jr, James F.
    Bril, Vera
    Vu, Tuan
    Karam, Chafic
    Peric, Stojan
    De Bleecker, Jan L.
    Murai, Hiroyuki
    Meisel, Andreas
    Beydoun, Said R.
    Pasnoor, Mamatha
    Guglietta, Antonio
    Van Hoorick, Benjamin
    Steeland, Sophie
    T'joen, Caroline
    Utsugisawa, Kimiaki
    Verschuuren, Jan
    Mantegazza, Renato
    FRONTIERS IN NEUROLOGY, 2024, 14
  • [43] Efficacy and safety of Efgartigimod in patients with generalized myasthenia gravis: interim results of a prospective, single-arm, observational study in China
    Liang, H.
    Wang, P.
    Zhang, B.
    Zhao, C.
    Huang, S.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S177 - S177
  • [44] Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC plus )
    Howard Jr, James F.
    Vu, Tuan
    Li, George
    Korobko, Denis
    Smilowski, Marek
    Liu, Li
    Gistelinck, Fien
    Steeland, Sophie
    Noukens, Jan
    Van Hoorick, Benjamin
    Podhorna, Jana
    Borgions, Filip
    Li, Yuebing
    Utsugisawa, Kimiaki
    Wiendl, Heinz
    De Bleecker, Jan L.
    Mantegazza, Renato
    NEUROTHERAPEUTICS, 2024, 21 (05)
  • [45] Randomized Phase 2 Study of FcRn Antagonist Efgartigimod in Generalized Myasthenia Gravis (vol 92, pg e2661, 2019)
    Howard Jr, J. F.
    Bril, V
    Burns, T. M.
    NEUROLOGY, 2025, 104 (03)
  • [46] A PHASE-3B OPEN-LABEL STUDY TO FURTHER INDIVIDUALIZE EFGARTIGIMOD TREATMENT OPTIONS FOR PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
    Gwathmey, Kelly
    Sahagian, Gregory
    Hussain, Yessar
    Feinberg, Marc
    Habib, Ali
    Skripuletz, Thomas
    Ruck, Tobias
    Brauer, Edward
    Gelinas, Deborah
    Zhao, Sihui
    Bogatyreva, Anna
    Mantegazza, Renato
    MUSCLE & NERVE, 2022, 66 : S141 - S142
  • [47] EFFICACY AND SAFETY OF TOLEBRUTINIB IN ADULTS WITH GENERALIZED MYASTHENIA GRAVIS: PHASE 3 STUDY DESIGN
    Barnett, Carolina
    Nicholson, Katharine
    Chen, Yixin
    Syed, Sana
    Turner, Timothy
    Smyth, Brendan
    Howard, James F., Jr.
    MUSCLE & NERVE, 2022, 66 : S127 - S128
  • [48] EFFICACY AND SAFETY OF TOLEBRUTINIB IN ADULTS WITH GENERALIZED MYASTHENIA GRAVIS: PHASE 3 STUDY DESIGN
    Barnett, Carolina
    Kaminski, Henry
    Benoit, Patrick
    Chen, Yixin
    Syed, Sana
    Turner, Timothy
    Smyth, Brendan
    Howard, James F., Jr.
    MUSCLE & NERVE, 2022, 66 : S47 - S48
  • [49] Real-World Case Series of Efgartigimod for Japanese Generalized Myasthenia Gravis: Well-Tailored Treatment Cycle Intervals Contribute to Sustained Symptom Control
    Konno, Shingo
    Uchi, Takafumi
    Kihara, Hideo
    Sugimoto, Hideki
    BIOMEDICINES, 2024, 12 (06)
  • [50] SELF-ADMINISTRATION OF SUBCUTANEOUS ROZANOLIXIZUMAB IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: CLINICAL STUDY DESIGN
    Mehta, Rachana K. Gandhi
    Bril, Vera
    Antozzi, Carlo
    Berkowicz, Tomasz
    Druzdz, Artur
    Mahuwala, Zabeen K.
    Zschuentzsch, Jana
    Flemm, Denis
    Lavrov, Andreea
    Morris, Mark
    Singh, Puneet
    Snipes, Rose
    Leite, M. Isabel
    MUSCLE & NERVE, 2024, 70 (03) : 529 - 529
12345